Qingxia Hu

Qingxia Hu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
QHQingxia Hu
Qingxia Hu
JYJunling Yin
Junling Yin
SZSijie Zhao
Sijie Zhao
YWYibo Wang
Yibo Wang
RSRuxue Shi
Ruxue Shi
SHShuhong Huang
Shuhong Huang
Zinc-finger homeobox 3 (ZFHX3, also known as ATBF1) suppresses prostatic tumorigenesis. ZFHX3 is frequently found to have numerous deletions in human prostate cancer (PCa). However, the underlying molecular function of ZFHX3 during prostatic tumorigenesis is not well understood. N6-methyladenosine (m6A) modification in RNA plays a critical role in the development of cancers; however, the relationship between ZFHX3 and m6A modification is largely unknown in PCa. In this study, we found that ZFHX3 knockdown decreased total m6A levels through enhancing the transcriptional activity of FTO in PCa cells. Importantly, FTO inhibition suppressed cell proliferation and rescued the promoting function of ZFHX3 knockdown on cell proliferation. In vivo, we verified that FTO was upregulated and ZFHX3 was decreased in PCa patients and that a high level of ZFHX3 is indispensable for low FTO expression and is correlated with better patient survival. Through transcriptome sequencing and MeRIP sequencing, we revealed that E2F2 and CDKN2C were the direct targets of FTO-mediated m6A modification and ZFXH3 was required for the regulation of FTO on E2F2 and CDKN2C expression. Unexpectedly, we uncovered that ZFHX3 expression was in return regulated by FTO in an m6A-dependent way. These findings establish a novel crosstalk mechanism between ZFHX3 and FTO in prostatic tumorigenesis.

10 April 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LXLinlin Xu
Linlin Xu
XLXinxing Lyu
Xinxing Lyu
YWYibo Wang
Yibo Wang
LNLi Ni
Li Ni
PLPin Li
Pin Li
NDNingning Dang
Ningning Dang
The Atg8-family proteins, including LC3B (microtubule-associated protein 1 light chain 3 beta), are pivotal for key steps in the autophagy process. Proper regulation of LC3B homeostasis is essential for its function. Although LC3B is modulated by various posttranslational modifications (PTMs), the impact of these modifications on LC3B protein homeostasis remains unclear. Neddylation, a recently identified ubiquitin-like modification, plays diverse biological roles. Here, we identify LC3B as a specific target for neddylation. This modification weakens LC3B’s interaction with the ubiquitin E3 ligases VHL and BIRC6, thereby reducing LC3B ubiquitination. Depletion of ubiquitin-conjugating enzyme E2M (UBE2M), the primary E2 enzyme in the neddylation pathway, destabilizes LC3B and suppresses autophagy activity. Heterozygous Ube2m knockout ( Ube2m +/− ) mice exhibit pronounced aging-like phenotypes, with reduced LC3B expression and impaired autophagy in skin tissues. Our findings demonstrate that LC3B neddylation is vital for maintaining its stability and regulating autophagy flux, offering a potential therapeutic avenue to mitigate aging-related processes.

28 May 2026 in Cell Death & Disease
Verified
Journal Article
Open access
YCYunhao Chang
Yunhao Chang
QCQiao Chen
Qiao Chen
XXXia Xu
Xia Xu
XLXinxing Lyu
Xinxing Lyu
LXLinlin Xu
Linlin Xu
BCBo Chen
Bo Chen
Pulmonary aging is characterized by progressive structural and functional decline. Neddylation is recognized as a crucial mechanism for maintaining cellular homeostasis; however, its function in pulmonary aging has not been fully elucidated. In this study, we found that the core neddylation E2 enzyme UBE2M was downregulated in aged lung tissues. Ube2m knockdown mice exhibited premature pulmonary aging, including vascular degeneration and structural disruption. Notably, in the lungs of knockout mice, although VEGF expression—primarily secreted by epithelial cells—remained unchanged, the protein level and phosphorylation of its receptor VEGFR2 on endothelial cells were significantly reduced. Mechanistic investigation confirmed that UBE2M directly regulates VEGFR2 stability in pulmonary endothelial cells via neddylation. In a doxorubicin-induced endothelial cell senescence model, UBE2M downregulation was accompanied by impaired VEGFR2 signaling, whereas UBE2M reconstitution partially alleviated cellular senescence. In elastase-induced emphysema mouse models and in lung tissues from COPD patients, both UBE2M and VEGFR2 levels were markedly reduced, and Ube2m deficiency exacerbated lung injury. In conclusion, this study demonstrates that UBE2M delays pulmonary aging by stabilizing VEGFR2 through neddylation, suggesting its potential as a therapeutic target for age-related pulmonary diseases.

1 March 2026 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
RSRuxue Shi
Ruxue Shi
KGKai Gu
Kai Gu
HLHaichuan Li
Haichuan Li
QSQingwei Sun
Qingwei Sun
XWXinyu Wu
Xinyu Wu
QHQingxia Hu
Qingxia Hu
Castration-resistant prostate cancer (CRPC) is one of the most prevalent cancers in men. The new generation androgen receptor (AR) inhibitor enzalutamide can improve the therapeutic effectiveness of patients with CRPC. However, these patients eventually develop acquired enzalutamide resistance (ENZR), and the mechanisms underlying resistance are not well understood. Wilms’ tumor 1-associating protein (WTAP) plays an important role in m6A modification and has been reported as an oncogene in various cancers. Here, we utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect WTAP expression, and found that WTAP is upregulated in PCa. Meanwhile, WTAP overexpression promotes cell proliferation and accelerates tumor growth through colony formation assays and the establishment of a subcutaneous xenograft model in vivo. These findings establish the tumor promoter role of WTAP in prostatic tumorigenesis. Furthermore, we verified that WTAP is a novel responsive gene of AR via promoter activity and chromatin immunoprecipitation (ChIP) assays. Importantly, we uncovered that WTAP is upregulated in ENZR cells, and WTAP knockdown inhibited the proliferation of ENZR cells. Mechanistically, ubiquitin-specific protease (USP7) enhanced the stability of WTAP by the ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increases promote AKT signaling through an m6A-mediated way, and an AKT inhibitor can abolish the pro-resistance phenotype mediated by WTAP. Together, these findings suggest that WTAP plays a key role in ENZR development of PCa cells, and WTAP may be a potential treatment target for ENZR tumors. In this manuscript, we utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect WTAP expression, and found that WTAP is upregulated in PCa. Meanwhile, WTAP overexpression promotes cell proliferation and accelerates tumor growth through colony formation assays and the establishment of a subcutaneous xenograft model in vivo. These findings establish the tumor promoter role of WTAP in prostatic tumorigenesis. Furthermore, we verified that WTAP is a novel responsive gene of AR via promoter activity and chromatin immunoprecipitation (ChIP) assays. Importantly, we uncovered that WTAP is upregulated in ENZR cells, and WTAP knockdown inhibited the proliferation of ENZR cells. Mechanistically, ubiquitin-specific protease (USP7) enhanced the stability of WTAP by the ubiquitin-proteasome pathway in ENZR cells, thereby WTAP increases promote AKT signaling through an m6A-mediated way, and an AKT inhibitor can abolish the pro-resistance phenotype mediated by WTAP. Together, these findings suggest that WTAP plays a key role in ENZR development of PCa cells, and WTAP may be a potential treatment target for ENZR tumors.